Insulin degludec and insulin degludec/insulin aspart: A review of their use in the management of diabetes mellitus

Drugs

Volumn 73, Issue 6, 2013, Pages 575-593

  Keating, Gillian M ^a  

^a Adis ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN GLARGINE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

CLINICAL TRIAL; DIABETES MELLITUS; DRUG SAFETY; DRUG TOLERABILITY; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NOCTURNAL HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG COMBINATIONS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN ANTAGONISTS; INSULIN ASPART; INSULIN, LONG-ACTING;

EID: 84878297344     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0051-1     Document Type: Review

References (69)

1. JS Skyler R Bergenstal RO Bonow, et al. 2009 Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association Diabetes Care 32 1 187 192 19092168 10.2337/dc08-9026
2. American Diabetes Association 2013 Standard of medical care in diabetes: 2013 Diabetes Care 36 Suppl 1 S11 S66 10.2337/dc13-S011
3. T Heise TR Pieber 2007 Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies Diabetes Obes Metab 9 5 648 659 17645556 10.1111/j.1463-1326.2007.00756. x 1:CAS:528:DC%2BD2sXhtFGgt7rP
4. S Arnolds B Kuglin C Kapitza, et al. 2010 How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes Int J Clin Pract 64 10 1415 1424 20618882 10.1111/j.1742-1241. 2010.02470.x 1:CAS:528:DC%2BC3cXhtFKrtbjE
5. GE Peterson 2006 Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir Curr Med Res Opin 22 12 2613 2619 17166343 10.1185/030079906X154178 1:CAS:528:DC%2BD2sXhsVOltLc%3D
6. SG Ashwell J Gebbie PD Home 2006 Twice-daily compared with once-daily insulin glargine in people with type 1 diabetes using meal-time insulin aspart Diabet Med 23 8 879 886 16911626 10.1111/j.1464-5491.2006.01913.x 1:CAS:528:DC%2BD28XpvFOjs7Y%3D
7. European Medicines Agency. Tresiba (insulin degludec): EU summary of product characteristics. 2013. http://www.emea.europa.eu/ema/. Accessed 1 Feb 2013.
8. European Medicines Agency. Ryzodeg (insulin degludec/insulin aspart): EU summary of product characteristics. 2013. http://www.emea.europa.eu/ema/. Accessed 1 Feb 2013.
9. Jonassen IB, Havelund S, Ribel U, et al. Insulin degludec is a new-generation ultra-long acting basal insulin with a unique mechanism of protraction based on multi-hexamer formation [abstract no. 39-OR]. 70th Annual Scientific Sessions of the American Diabetes Association; Orlando, FL; 25-29 June 2010.
10. P Kurtzhals T Heise HM Strauss, et al. 2011 Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec [abstract no. 1049] Diabetologia 54 Suppl 1 S426
11. T Seested S Havelund IB Jonassen, et al. 2012 Ultrastructural visualisation of insulin degludec multi-hexamers in the subcutaneous depot in vivo supports a unique mechanism of protraction [abstract no. 980-P] Diabetes 61 Suppl 1 A250
12. I Jonassen T Hoeg-Jensen S Havelund, et al. 2010 Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation [abstract no 380] J Pept Sci 16 Suppl 1 32
13. E Nishimura AR Sørensen BF Hansen, et al. 2010 Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential [abstract no. 974] Diabetologia 53 Suppl 1 S388 S389
14. L Nosek H-V Coester HF Thomsen, et al. 2012 Glucose-lowering effect of insulin degludec is independent of subcutaneous injection region [abstract no. 899-P] Diabetes 61 Suppl 1 A228
15. Korsatko S, Deller S, Zahiragic S, et al. Ultra-long-acting insulin degludec: two different formulations (U100 and U200) are bioequivalent and show similar pharmacodynamics [abstract no. 2349-PO]. Diabetes. 2011;60 Suppl:A624.
16. U Hövelmann T Heise L Nosek, et al. 2012 Insulin degludec 200 U/ml is ultra-long-acting and has a flat and stable glucose-lowering effect [abstract no. 912] Diabetologia 55 Suppl 1 S374 S375
17. T Heise L Nosek SG Bøttcher, et al. 2012 Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes Diabetes Obes Metab 14 10 944 950 22726241 10.1111/j.1463-1326.2012.01638.x 1:CAS:528:DC%2BC38XhtlSmtL3M
18. SN Nasrallah LR Reynolds 2012 Insulin degludec, the new generation basal insulin or just another basal insulin? Clin Med Insights Endocrinol Diabetes 5 31 37 22879797 10.4137/CMED.S9494 1:CAS:528:DC%2BC38Xmtlyrt7g%3D
19. DB Steensgaard G Schluckebier HM Strauss, et al. 2013 Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec Biochemistry (Moscow) 52 2 295 309 10.1021/bi3008609 1:CAS:528:DC%2BC38XhvVKmsbrP
20. I Jonassen S Havelund T Hoeg-Jensen, et al. 2012 Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin Pharm Res 29 8 2104 2114 22485010 10.1007/s11095-012-0739-z 1:CAS:528: DC%2BC38XltF2jsrc%3D
21. JD Robinson JJ Neumiller RK Campbell 2012 Can a new ultra-long acting insulin analog improve patient care? Investigating the potential role of insulin degludec Drugs 72 18 2319 2325 23145524 10.2165/11642240-000000000-00000 1:CAS:528:DC%2BC3sXit1Wru7o%3D
22. IB Hirsch B Bode J-P Courreges, et al. 2012 Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial Diabetes Care 35 11 2174 2181 22933438 10.2337/dc11-2503 1:CAS:528:DC%2BC38XhvFShs7nP
23. European Medicines Agency. Insulin degludec/insulin aspart: CHMP assessment report. 2013. http://www.emea.europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment-report/human/002499/WC500139013.pdf. Accessed 28 Feb 2013.
24. T Heise L Hermanski L Nosek, et al. 2012 Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes Diabetes Obes Metab 14 9 859 864 22594461 10.1111/j.1463-1326.2012.01627.x 1:CAS:528:DC%2BC38XhtFOmsLbL
25. NA Reynolds AJ Wagstaff 2004 Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus Drugs 64 17 1957 1974 15329046 10.2165/00003495-200464170-00013 1:CAS:528:DC%2BD2cXoslGltbo%3D
26. T Heise U Hövelmann L Nosek, et al. 2011 Insulin degludec: two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine [abstract no. 1046] Diabetologia 54 Suppl 1 S425
27. HL Haahr G Arold SG Bottcher, et al. 2012 Insulin degludec has similar pharmacokinetic properties in subjects with renal impairment and subjects with normal renal function [abstract no. 923] Diabetologia 55 Suppl 1 S379
28. Arold G, Kupčová V, Thrane M, et al. Insulin degludec has similar pharmacokinetic properties in subjects with hepatic impairment when compared to subjects with normal hepatic function [abstract no. 1119-P]. Diabetes. 2012;61 Suppl:A289.
29. T Danne T Biester S Blaesig, et al. 2011 Ultra-long pharmacokinetic properties of insulin degludec in adults with type 1 diabetes is preserved in children and adolescents after single-dose administration [abstract no. 1047] Diabetologia 54 Suppl 1 S425 S426
30. S Korsatko S Deller J Mader, et al. 2012 Ultra-long pharmacokinetic properties of insulin degludec in younger adults are preserved in geriatric subjects with type 1 diabetes [abstract no. 924] Diabetologia 55 Suppl 1 S379 S380
31. M Hompesch L Morrow E Watkins, et al. 2012 Insulin degludec provides similar pharmacokinetic and pharmacodynamic responses in Black, White and Hispanic/Latino patients with type 2 diabetes [abstract no. 925] Diabetologia 55 Suppl 1 S380
32. European Medicines Agency. Insulin degludec: CHMP assessment report. 2013. http://www.emea.europa.eu/docs/en-GB/document-library/EPAR-Public- assessment-report/human/002498/WC500139010.pdf. Accessed 28 Feb 2013.
33. Bergenstal R, Bhargava A, Jain R, et al. 200 U/mL insulin degludec improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve people with type 2 diabetes [abstract no. 207]. American Association of Clinical Endocrinologists 21st Annual Scientific and Clinical Congress; Philadelphia, PA; 23-27 May 2012.
34. KI Birkeland PD Home U Wendisch, et al. 2011 Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine Diabetes Care 34 3 661 665 21270174 10.2337/dc10-1925
35. B Zinman G Fulcher PV Rao, et al. 2011 Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial Lancet 377 9769 924 931 21396703 10.1016/S0140- 6736(10)62305-7 1:CAS:528:DC%2BC3MXjtFWgsL4%3D
36. S Heller J Buse M Fisher, et al. 2012 Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 379 9825 1489 1497 22521071 10.1016/S0140-6736(12)60204-9 1:CAS:528: DC%2BC38XlvFKlsbY%3D
37. C Mathieu P Hollander B Miranda-Palma, et al. 2013 Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension J Clin Endocrinol Metab 98 3 1154 1162 23393185 10.1210/jc.2012-3249 1:CAS:528:DC%2BC3sXksFymu7o%3D
38. Y Onishi SW Park SJ Yoo, et al. 2012 Insulin degludec improves glycemic control in insulin-naïve patients with type 2 diabetes: results of a randomized pan-Asian trial [abstract no. 1059-P] Diabetes 61 Suppl 1 A272
39. B Zinman A Philis-Tsimikas B Cariou, et al. 2012 Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long) Diabetes Care 35 12 2464 2471 23043166 10.2337/dc12-1205 1:CAS:528:DC%2BC38XhvFShsrvL
40. AJ Garber AB King S Del Prato, et al. 2012 Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial Lancet 379 9825 1498 1507 22521072 10.1016/S0140-6736(12)60205-0 1:CAS:528: DC%2BC38XlvFKhsrc%3D
41. A Philis-Tsimikas S Del Prato I Satman, et al. 2012 Insulin degludec is superior to sitagliptin in improving glycaemic control in uncontrolled patients with type 2 diabetes on oral agents [abstract no. 40] Diabetologia 55 Suppl 1 S22
42. L Meneghini SL Atkin SC Gough, et al. 2013 The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in people with type 2 diabetes Diabetes Care 36 4 858 864 23340894 10.2337/dc12-1668
43. HW Rodbard Y Handelsman B Cariou, et al. 2012 Insulin degludec reduces hypoglycemia and improves health status vs. insulin glargine in insulin-naïve type 2 diabetes [abstract no. 1192-P] Diabetes 61 Suppl 1 A307 A308
44. HW Rodbard B Zinman B Cariou, et al. 2012 Reduced nocturnal hypoglycaemia with insulin degludec as compared to insulin glargine: results of a 2-year randomised trial in type 2 diabetes [abstract no. 920] Diabetologia 55 Suppl 1 S378
45. Novo Nordisk. Comparison of NN1250 with sitagliptin in subjects with type 2 diabetes never treated with insulin [ClinicalTrials.gov identifier NCT01046110]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://www.clinicaltrials.gov. Accessed 13 Nov 2012.
46. Novo Nordisk. Comparison of NN1250 versus insulin glargine in subjects with type 2 diabetes (BEGIN™) [ClinicalTrials.gov identifier NCT01059799]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://www.clinicaltrials.gov. Accessed 13 Nov 2012.
47. Novo Nordisk. Comparison of NN1250 with insulin glargine in subjects with type 2 diabetes (BEGIN™) [ClinicalTrials.gov identifier NCT01068665]. US National Institutes of Health, ClinicalTrials.gov (online). 2011. http://www.clinicaltrials.gov. Accessed 15 Nov 2012.
48. ®) compared with insulin glargine in people with type 2 diabetes starting on basal insulin: a meta-analysis of phase 3a trials Diabet Med 30 2 226 232 23199058 10.1111/dme.12086 1:CAS:528:DC%2BC3sXjt1elurY%3D
49. T Heise CJ Tack R Cuddihy, et al. 2011 A new-generation ultra-long-acting basal insulin with a bolus boost compared with insulin glargine in insulin-naïve people with type 2 diabetes: a randomized, controlled trial Diabetes Care 34 3 669 674 21285389 10.2337/dc10-1905 1:CAS:528: DC%2BC3MXjvFOgs70%3D
50. S Nakamura Y Ono R Rabøl, et al. 2012 Superior glycaemic control with once-daily IDegAsp vs insulin glargine in Japanese adults with type 2 diabetes mellitus inadequately controlled with OADs: a randomised controlled, phase 3 trial [abstract no. 949] Diabetologia 55 Suppl 1 S390
51. L Niskanen LA Leiter E Franek, et al. 2012 Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial Eur J Endocrinol 167 2 287 294 22660026 1:CAS:528:DC%2BC38Xht1Cgsb3F
52. Novo Nordisk. Comparison of NN5401 with insulin glargine in insulin naive subjects with type 2 diabetes (BOOST™) [ClinicalTrials.gov identifier NCT01272193]. US National Institutes of Health, ClinicalTrials.gov (online). 2012. http://www.clinicaltrials.gov. Accessed 15 Nov 2012.
53. US Food and Drug Administration. FDA briefing document: NDA 203313 and NDA 203314 (insulin degludec and insulin degludec/insulin aspart. 2012. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM327015.pdf. Accessed 28 Feb 2013.
54. R Ratner SCL Gough C Mathieu, et al. 2013 Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: pre-planned meta-analysis of phase 3 trials Diabetes Obes Metab 15 2 175 184 23130654 10.1111/dom.12032 1:CAS:528:DC%2BC3sXjs1SqsQ%3D%3D
55. M Muggeo G Verlato E Bonora, et al. 1997 Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent diabetes mellitus: the Verona Diabetes Study Circulation 96 6 1750 1754 9323057 10.1161/01.CIR.96.6.1750 1:STN:280:DyaK2svmt1ygsg%3D%3D
56. European Medicine Agency. Lantus (insulin glargine): EU summary of product characteristics. 2012. http://www.emea.europa.eu/docs/en-GB/document- library/EPAR-Product-Information/human/000284/WC500036082.pdf. Accessed 15 Mar 2013.
57. A Wakil SL Atkin 2012 Efficacy and safety of ultra-long-acting insulin degludec Ther Adv Endocrinol Metab 3 2 55 59 23148194 10.1177/2042018812437181 1:CAS:528:DC%2BC38XovVymt74%3D
58. American Diabetes Association Workgroup on Hypoglycemia 2005 Defining and reporting hypoglycaemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia Diabetes Care 28 5 1245 1249 10.2337/diacare.28.5.1245
59. European Medicine Agency. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2012/ 06/WC500129256.pdf. Accessed 4 Apr 2013.
60. AA Tahrani CJ Bailey AH Barnett 2012 Insulin degludec: a new ultra-longacting insulin Lancet 379 9825 1465 1467 22521058 10.1016/S0140- 6736(12)60527-3
61. GM Keating 2012 Insulin detemir: a review of its use in the management of diabetes mellitus Drugs 72 17 2255 2287 23110609 10.2165/11470200-000000000- 00000 1:CAS:528:DC%2BC3sXovVCiuw%3D%3D
62. ® (media release). 2013. http://www.novonordisk.com/include/asp/exe-news-attachment.asp?sAttachmentGUID= 83700060-0ce3-4577-a35a-f3e57801637d. Accessed 7 Mar 2013.
63. Pharmaceuticals and Medical Devices Agency. Insulin degludec submission file. 2013. http://www.pmda.go.jp/index.html. Accessed 5 Apr 2013.
64. ® now ready to be launched in Japan (media release). 2013. http://novonordisk.com/investors/sea/sea.asp? sNewsTypeGUID=&lMonth=&lYear=&sLanguageCode=&sSearchText= &fb=4350&cat=pr&sShowNewsItemGUID=33a77fce-8192-47d1-a360- 68275268a048&sShowLanguageCode=en-GB. Accessed 4 Apr 2013.
65. E Giovannucci DM Harlan MC Archer, et al. 2010 Diabetes and cancer: a consensus report Diabetes Care 33 7 1674 1685 20587728 10.2337/dc10-0666
66. A Dejgaard H Lynggaard J Råstam, et al. 2009 No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis Diabetologia 52 12 2507 2512 19838665 10.1007/s00125-009-1568-4 1:STN:280:DC%2BC3c%2Fjslemtw%3D%3D
67. M Evans PM Schumm-Draeger J Vora, et al. 2011 A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations Diabetes Obes Metab 13 8 677 684 21410860 10.1111/j.1463-1326.2011.01395.x 1:CAS:528:DC%2BC3MXhtVWqu7bP
68. HC Gerstein J Bosch GR Dagenais, et al. 2012 Basal insulin and cardiovascular and other outcomes in dysglycemia N Engl J Med 367 4 319 328 22686416 10.1056/NEJMoa1203858 1:CAS:528:DC%2BC38XhtFegsrvN
69. F Wang J Surh M Kaur 2012 Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review Diabetes Metab Syndr Obes 5 191 204 22826637 10.2147/DMSO.S21979 1:CAS:528:DC%2BC38XhtVChsr%2FE